^OVERVIEW

PF-08052666 is an ADC that targets human mesothelin⁶

^{RATIONALE  FOR CANCER TARGET:}

• Mesothelin (MSLN) is a cell-surface protein overexpressed in numerous solid tumors, including ovarian, pancreatic, endometrial, gastric, lung, and colorectal cancers, with limited expression in normal tissues making it an attractive ADC target​¹
• ​To-date, results from initial clinical trials have validated MSLN as an attractive target for cancer therapy and several anti-MSLN ADCs have been used to deliver anti-tubulin payloads with manageable safety, but modest efficacy^2-4
• Tumors overexpressing MSLN are known to be sensitive to topoisomerase inhibitors with irinotecan/topotecan approved for treatment of ovarian, colorectal and pancreatic cancers⁵